Sweden's Nanexa Q4 revenue jumps

Reuters

Feb 19

Overview

Sweden drug delivery firm reported Q4 revenue up significantly yr/yr
Company announced license and option agreement with Moderna
Company converted 8.5 mln warrants into shares, raising SEK 17 mln

Outlook

Nanexa sees favorable conditions for 2026 due to Moderna agreement

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Revenue		SEK 30.09 mln
Q4 EPS		SEK 0.10
Q4 Net Income		SEK 16.04 mln
Q4 EBIT		SEK 16.67 mln

Analyst Coverage

The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 14 three months ago

Press Release: ID:nMFN95N9Bn

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2612816470"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612816470\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612816470?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-19 15:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612816470","market":"fut","top_or_hot":-1,"title":"Sweden's Nanexa Q4 revenue jumps","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Sweden's Nanexa Q4 revenue jumps </title></head><body>Overview<ul><li>Sweden drug delivery firm reported Q4 revenue up significantly yr/yr</li><li>Company announced license and option agreement with <a href=\"https://laohu8.com/S/MRNA\">Moderna</a></li><li>Company converted 8.5 mln warrants into shares, raising SEK 17 mln</li></ul>Outlook<ul><li>Nanexa sees favorable conditions for 2026 due to Moderna agreement</li></ul>Key Details<table><tbody><tr><td>Metric</td><td>Beat/Miss</td><td>Actual</td><td>Consensus Estimate</td></tr><tr><td>Q4 Revenue</td><td></td><td>SEK 30.09 mln</td><td></td></tr><tr><td>Q4 EPS</td><td></td><td>SEK 0.10</td><td></td></tr><tr><td>Q4 Net Income</td><td></td><td>SEK 16.04 mln</td><td></td></tr><tr><td>Q4 EBIT</td><td></td><td>SEK 16.67 mln</td><td></td></tr></tbody></table>Analyst Coverage<ul><li>The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 14 three months ago</li></ul>Press Release: ID:nMFN95N9BnFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sweden's Nanexa Q4 revenue jumps</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSweden's Nanexa Q4 revenue jumps\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\nReuters \n2026-02-19 15:13\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Sweden's Nanexa Q4 revenue jumps </title></head><body>Overview<ul><li>Sweden drug delivery firm reported Q4 revenue up significantly yr/yr</li><li>Company announced license and option agreement with <a href=\"https://laohu8.com/S/MRNA\">Moderna</a></li><li>Company converted 8.5 mln warrants into shares, raising SEK 17 mln</li></ul>Outlook<ul><li>Nanexa sees favorable conditions for 2026 due to Moderna agreement</li></ul>Key Details<table><tbody><tr><td>Metric</td><td>Beat/Miss</td><td>Actual</td><td>Consensus Estimate</td></tr><tr><td>Q4 Revenue</td><td></td><td>SEK 30.09 mln</td><td></td></tr><tr><td>Q4 EPS</td><td></td><td>SEK 0.10</td><td></td></tr><tr><td>Q4 Net Income</td><td></td><td>SEK 16.04 mln</td><td></td></tr><tr><td>Q4 EBIT</td><td></td><td>SEK 16.67 mln</td><td></td></tr></tbody></table>Analyst Coverage<ul><li>The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 14 three months ago</li></ul>Press Release: ID:nMFN95N9BnFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4548","symbol_name":"巴美列捷福持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nL1N3ZF099:1","article_id":"2612816470","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612816470","pubTimestamp":1771485219,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sweden's Nanexa Q4 revenue jumpsOverviewSweden drug delivery firm reported Q4 revenue up significantly yr/yrCompany announced license and option agreement with ModernaCompany converted 8.5 mln warrant","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4548":"巴美列捷福持仓","BK4139":"生物科技","BK4532":"文艺复兴科技持仓","BK4568":"美国抗疫概念","BK4585":"ETF&股票定投概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4551":"寇图资本持仓","BK4501":"段永平概念","BK4588":"碎股","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓"},"translate_title":"瑞典Nanexa第四季度收入猛增","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9},"content_text":"Sweden's Nanexa Q4 revenue jumps OverviewSweden drug delivery firm reported Q4 revenue up significantly yr/yrCompany announced license and option agreement with ModernaCompany converted 8.5 mln warrants into shares, raising SEK 17 mlnOutlookNanexa sees favorable conditions for 2026 due to Moderna agreementKey DetailsMetricBeat/MissActualConsensus EstimateQ4 RevenueSEK 30.09 mlnQ4 EPSSEK 0.10Q4 Net IncomeSEK 16.04 mlnQ4 EBITSEK 16.67 mlnAnalyst CoverageThe stock recently traded at 27 times the next 12-month earnings vs. a P/E of 14 three months agoPress Release: ID:nMFN95N9BnFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}